CAR T Cell Therapy: Who would benefit from this therapy?

Karmanos Cancer Institute

“Karmanos is very pleased to have been part of the treatment study which earned FDA approval after decades of research, now making this treatment available to more patients with this challenging disease. This is good news for those with diffuse large B-cell lymphoma, since the success rate with other types of treatment has been minimal,” said Abhinav Deol, M.D., medical oncologist, Karmanos Cancer Institute and associate professor, Wayne State University School of Medicine.